Navis G - Search Results

1

Indomethacin reduces glomerular and tubular damage markers but not renal inflammation in chronic kidney disease patients: a post-hoc analysis.

de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, Navis G. de Borst MH, et al. Among authors: navis g. PLoS One. 2012;7(5):e37957. doi: 10.1371/journal.pone.0037957. Epub 2012 May 25. PLoS One. 2012. PMID: 22662255 Free PMC article.

2

Transient post-renal obstruction may protect the kidney against nephrotoxic damage--a case report.

Navis GJ, Rommes JH, Baur C, de Jong PE. Navis GJ, et al. Intensive Care Med. 1995 Jul;21(7):610-1. doi: 10.1007/BF01700171. Intensive Care Med. 1995. PMID: 7593907

3

Proteinuria and progression of renal disease: therapeutic implications.

Gansevoort RT, Navis GJ, Wapstra FH, de Jong PE, de Zeeuw D. Gansevoort RT, et al. Among authors: navis gj. Curr Opin Nephrol Hypertens. 1997 Mar;6(2):133-40. doi: 10.1097/00041552-199703000-00005. Curr Opin Nephrol Hypertens. 1997. PMID: 9146974 Review.

4

ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.

van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Scheffer H, de Zeeuw D, de Jong PE. van der Kleij FG, et al. Among authors: navis gj. Nephrol Dial Transplant. 1997;12 Suppl 2:42-6. Nephrol Dial Transplant. 1997. PMID: 9269699

5

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D. Laverman GD, et al. Among authors: navis g. Am J Kidney Dis. 2001 Dec;38(6):1381-4. doi: 10.1053/ajkd.2001.29262. Am J Kidney Dis. 2001. PMID: 11728979 Clinical Trial.

6

Dual renin-angiotensin system blockade at optimal doses for proteinuria.

Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Laverman GD, et al. Among authors: navis g. Kidney Int. 2002 Sep;62(3):1020-5. doi: 10.1046/j.1523-1755.2002.00536.x. Kidney Int. 2002. PMID: 12164886 Free article. Clinical Trial.

7

Renoprotection: a matter of blood pressure reduction or agent-characteristics?

Vogt L, Navis G, de Zeeuw D. Vogt L, et al. Among authors: navis g. J Am Soc Nephrol. 2002 Nov;13 Suppl 3:S202-7. doi: 10.1097/01.asn.0000032489.33856.53. J Am Soc Nephrol. 2002. PMID: 12466315 Review.

8

Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.

Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Laverman GD, et al. Among authors: navis g. Kidney Int. 2003 Jan;63(1):64-71. doi: 10.1046/j.1523-1755.2003.00708.x. Kidney Int. 2003. PMID: 12472769 Free article.

9

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?

Laverman GD, de Zeeuw D, Navis G. Laverman GD, et al. Among authors: navis g. J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):205-13. doi: 10.3317/jraas.2002.042. J Renin Angiotensin Aldosterone Syst. 2002. PMID: 12584664 Free article. Review.

10

The COOPERATE trial.

Vogt L, Laverman GD, de Zeeuw D, Navis G. Vogt L, et al. Among authors: navis g. Lancet. 2003 Mar 22;361(9362):1055-6. doi: 10.1016/S0140-6736(03)12803-6. Lancet. 2003. PMID: 12660079 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters